
First topical PDE4 inhibitor approved for plaque psoriasis
Recently, Arcutis Biotherapeutics announced that the FDA approved the topical selective PDE4 inhibitor ZORYVE (Roflumilast, roflumilast) cream 0.3% for the treatment of plaque psoriasis in
Recently, Arcutis Biotherapeutics announced that the FDA approved the topical selective PDE4 inhibitor ZORYVE (Roflumilast, roflumilast) cream 0.3% for the treatment of plaque psoriasis in